Immuneering Corporation (IMRX)
Immuneering Statistics
Share Statistics
Immuneering has 31.05M shares outstanding. The number of shares has increased by 6.03% in one year.
| Shares Outstanding | 31.05M |
| Shares Change (YoY) | 6.03% |
| Shares Change (QoQ) | 4.71% |
| Owned by Institutions (%) | 14.59% |
| Shares Floating | 22.4M |
| Failed to Deliver (FTD) Shares | 5.61K |
| FTD / Avg. Volume | 0.28% |
Short Selling Information
The latest short interest is 2.05M, so 6.59% of the outstanding shares have been sold short.
| Short Interest | 2.05M |
| Short % of Shares Out | 6.59% |
| Short % of Float | 9.13% |
| Short Ratio (days to cover) | 1.19 |
Valuation Ratios
The PE ratio is -3.91 and the forward PE ratio is -1.18. Immuneering's PEG ratio is -7.3.
| PE Ratio | -3.91 |
| Forward PE | -1.18 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 2.31 |
| P/FCF Ratio | -4.24 |
| PEG Ratio | -7.3 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immuneering Corporation.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.35, with a Debt / Equity ratio of 0.05.
| Current Ratio | 11.35 |
| Quick Ratio | 11.35 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.7 |
| Cash Flow / Debt | -10.97 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -61.46%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.52% |
| Return on Capital (ROIC) | -61.46% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-810,176.09 |
| Employee Count | 66 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.17% in the last 52 weeks. The beta is -0.37, so Immuneering's price volatility has been lower than the market average.
| Beta | -0.37 |
| 52-Week Price Change | -73.17% |
| 50-Day Moving Average | 1.96 |
| 200-Day Moving Average | 1.75 |
| Relative Strength Index (RSI) | 35.58 |
| Average Volume (20 Days) | 2.01M |
Income Statement
| Revenue | n/a |
| Gross Profit | -764.14K |
| Operating Income | -58.41M |
| Net Income | -53.47M |
| EBITDA | -58.06M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.88 |
Balance Sheet
The company has 59.41M in cash and 4.46M in debt, giving a net cash position of 54.94M.
| Cash & Cash Equivalents | 59.41M |
| Total Debt | 4.46M |
| Net Cash | 54.94M |
| Retained Earnings | -163.26M |
| Total Assets | 68.56M |
| Working Capital | 48.34M |
Cash Flow
In the last 12 months, operating cash flow was -48.97M and capital expenditures -342.75K, giving a free cash flow of -49.31M.
| Operating Cash Flow | -48.97M |
| Capital Expenditures | -342.75K |
| Free Cash Flow | -49.31M |
| FCF Per Share | -1.74 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -113.94% |
| FCF Yield | -96.25% |
Analyst Forecast
The average price target for IMRX is $10, which is 506.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 506.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -4.73 |
| Piotroski F-Score | 1 |